期刊
CANCER LETTERS
卷 224, 期 1, 页码 117-121出版社
ELSEVIER IRELAND LTD
DOI: 10.1016/j.canlet.2004.10.010
关键词
epidermal growth factor receptor; mutation; hepatocellular carcinoma
类别
The epidermal growth factor receptor (EGFR) is overexpressed in many epithelial tumors and plays an important role in the turnorigenesis of these tumors. Inhibitors of EGFR reduce the proliferation rate of cancers and are promising therapeutic agents of cancers. Recently, two studies have identified somatic mutations in the exons 18-21 of EGFR that were strongly correlated with robust clinical response to gefitinib treatment in patients with non-small cell lung cancer. To investigate whether EGFR mutation is involved in the tumorigenesis of hepatocellular carcinoma (HCC), we performed direct sequencing of exons 18-21 on 89 HCCs. No mutations causing amino acid changes or deletions were identified. The results indicate mutation of the kinase domain of EGFR does not play a significant role in the tumorigenesis of HCC and gefitinib is unlikely to be used as single-drug therapy for HCC. (c) 2004 Elsevier Ireland Ltd. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据